30
Participants
Start Date
June 5, 2024
Primary Completion Date
January 30, 2027
Study Completion Date
January 30, 2027
BET Bromodomain Inhibitor ZEN-3694
Given PO
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo collection of blood samples
Cetuximab
Given IV
Computed Tomography
Undergo CT
Echocardiography Test
Undergo ECHO
Encorafenib
Given PO
Magnetic Resonance Imaging
Undergo MRI
Multigated Acquisition Scan
Undergo MUGA
RECRUITING
University of Virginia Cancer Center, Charlottesville
RECRUITING
VCU Massey Comprehensive Cancer Center, Richmond
RECRUITING
Ohio State University Comprehensive Cancer Center, Columbus
RECRUITING
University of Kansas Cancer Center, Kansas City
RECRUITING
University of Kansas Clinical Research Center, Fairway
RECRUITING
University of Kansas Hospital-Westwood Cancer Center, Westwood
RECRUITING
University of Kansas Hospital-Indian Creek Campus, Overland Park
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
RECRUITING
M D Anderson Cancer Center, Houston
RECRUITING
UCHealth University of Colorado Hospital, Aurora
RECRUITING
Los Angeles General Medical Center, Los Angeles
RECRUITING
USC / Norris Comprehensive Cancer Center, Los Angeles
National Cancer Institute (NCI)
NIH